Key result
Implantation of the XIENCE PRIME Everolimus Elution Coronary Stent System was associated with a 5-year cumulative major adverse cardiac event rate of 10.0% and target lesion failure rate of 3.3%.
Why the study?
This study was aimed at evaluating the 5-year effectiveness and safety in participants after XIENCE PRIME Everolimus Elution Coronary Stent System implantation.
Cohort (n=108)
The XIENCE PRIME everolimus-eluting stent demonstrates favorable long-term safety and effectiveness at 5 years, with low rates of target lesion failure and stent thrombosis.
Supports real-world long-term safety of everolimus-eluting stents; leaves open need for randomized confirmation.
Background/aim: This study was aimed at evaluating 5-year effectiveness and safety in participants after XIENCE PRIME Everolimus Elution Coronary Stent System (EECSS) implantation. Materials and methods: From December 2013 to May 2014, 108 patients (127 lesions) were treated with the XIENCE PRIME EECSS. The entire follow-up included annual assessments for 5 years after treatment or until one of the clinical endpoints was reached. We evaluated the 5-year clinical outcomes with Kaplan-Meier analysis and the Cox regression model. Results: Nearly three-quarters of the participants were men (76.8%), and the average age was 65.6 ± 10.8 years. Bifurcation lesions accounted for 96.1% (122 lesions), and left main lesions accounted for 3.9% (five lesions), with a total count of 127 lesions. The cumulative rate of major adverse cardiac events was as follows: 1 year, 1.9%; 2 year, 4.0%; and 5 year, 10.0%. No definite or probable stent thrombosis was observed, and the rate of target lesion failure was only 3.3% over 5 years. The cumulative rate of major bleeding eventually increased to only 4.4%. Conclusions: The 5-year clinical outcomes were favorable in patients treated with XIENCE PRIME EECSS, and the incidence of stent thrombosis and target lesion failure was relatively low. The incidence of major bleeding gradually increased but remained moderate.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2023) conducted a cohort in Coronary artery disease (n=108). XIENCE PRIME Everolimus Elution Coronary Stent System was evaluated on major adverse cardiac events. Implantation of the XIENCE PRIME Everolimus Elution Coronary Stent System was associated with a 5-year cumulative major adverse cardiac event rate of 10.0% and target lesion failure rate of 3.3%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: